Danusertib is primarily used in the field of oncology as an investigational drug targeting cancer treatment. It functions as an Aurora kinase inhibitor, which plays a crucial role in cell division and proliferation. By inhibiting these kinases, Danusertib disrupts the growth and survival of cancer cells, particularly in tumors that rely on these pathways. It has shown potential in treating various cancers, including prostate, breast, and hematologic malignancies. Clinical trials are ongoing to evaluate its efficacy and safety, with a focus on its ability to overcome resistance to other therapies. Additionally, research explores its use in combination with other anticancer agents to enhance treatment outcomes.